MARKET

ZYME

ZYME

Zymeworks
NASDAQ
11.73
+0.41
+3.58%
Opening 13:08 05/09 EDT
OPEN
11.38
PREV CLOSE
11.32
HIGH
12.19
LOW
11.32
VOLUME
236.35K
TURNOVER
--
52 WEEK HIGH
17.70
52 WEEK LOW
8.21
MARKET CAP
815.79M
P/E (TTM)
-7.2479
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Joint (JYNT)
TipRanks · 3h ago
Zymeworks Reports Q1 2025 Financial Results and R&D Progress
TipRanks · 12h ago
Zymeworks outlines robust pipeline advancements and financial resilience through 2027
Seeking Alpha · 14h ago
Zymeworks: Strategic Positioning and Financial Health Drive Buy Rating
TipRanks · 16h ago
Zymeworks Updates Communication Channels for Stakeholders
TipRanks · 20h ago
ZYMEWORKS INC. QUARTERLY REPORT ON FORM 10-Q For the Quarter Ended March 31, 2025
Press release · 20h ago
BRIEF-Zymeworks Q1 Operating Expenses USD 52.723 Million
Reuters · 21h ago
Press Release: Zymeworks Provides Corporate -2-
Dow Jones · 21h ago
More
About ZYME
More
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Recently
Symbol
Price
%Change

Webull offers Zymeworks Inc stock information, including NASDAQ: ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.